Phase I Clinical Trial to Assess the Safety and Pharmacokinetic Profile of CKD-516 Inj. Administered on A Twice-Weekly Schedule in Patients With Advanced Solid Cancers Failed to Standard Therapy
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2015
At a glance
- Drugs CKD 516 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chong Kun Dang
- 20 Aug 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 29 Aug 2012 New source identified and integrated (Clinical Research Information Service (CriS) - Republic of Korea, KCT0000499).
- 25 Jul 2012 Actual initiation date (Jun 2012) added as reported by ClinicalTrials.gov.